Hypertension is recognized as an important global public-health challenge. High blood pressure
is the foremost controllable risk factor for morbidity and mortality and is a major independent risk
factor for the development of coronary artery disease, stroke, and renal failure. The hypertension affected
overall, 26.4% of world’s adult population in 2000, and the figure is expected to increase by about
60%; i.e. to 29.2% of total adult population by the year 2025. There are several therapeutic options for
the management of hypertension, dependent upon the overall status of disease. The Angiotensin Converting
Enzyme (ACE) inhibitors are rated as first-line treatment in the effective management of hypertension.
However, the current AEC inhibitors in clinical practice are nonselective inhibitors and thus
causing several unwanted effects. Therefore, new selective inhibitors have been focused around the
world by various researchers for the discovery safer agents. The phytopharmaceuticals such as alkaloids
have a marvelous therapeutic history and numerous alkaloids are in clinical use, therefore it could be an
ideal approach to study for the design of selective inhibitors. This review encountered the so far tested
alkaloids and their significant results thus suggested further study of these and many, more alkaloids for
the discovery of new effective and selective ACE inhibitors. Furthermore, the application of modern
pharmaceutical technologies could be helpful in the effective design of agents.
Keywords: Phytoalkaloids, ACE inhibition, preclinical status, drugs of future/selective inhibition, alkaloids, hypertension.
Rights & PermissionsPrintExport